Phase 2 N=11 Continuation Study of the Oral AKT Inhibitor GSK2110183
Cancer
Primary: Number of Participants With at Least One Adverse Events (AEs) — 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=6 Safety & Tolerability of Hypertonic Saline Administration Via Intraosseous Access
Stroke · Intracranial Hypotension · Cerebral Edema
Primary: Number of Subjects With Tissue Damage — 0 Participants
Phase 2 N=200 Efficacy of Enteral Iron Supplementation in Critical Illness
Anemic, Critically Ill Patients
Primary: Hematocrit — 29.3; 29.1; 28.6; 28.2 percentage of RBC in blood
Phase 2 N=45 MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients
Ulcerative Colitis
Primary: Number of Participants With Remission at Week 8 — 0; 1; 2; 1 Participants
Phase 2 N=23 Study of Gefapixant (MK-7264) in Adult Japanese Participants With Unexplained or Refractory Chronic Cough (MK-7264-033)
Chronic Cough
Primary: Number of Participants Who Experienced an Adverse Event — 9; 2 Participants
Phase 2 N=63 Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Docetaxel as Neoadjuvant Treatment of Breast Cancer Patients
Breast Cancer
Primary: Pathological Complete Response (pCR) Rate — 11 Participants
Phase 2 N=374 Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)
Urothelial Cancer
Primary: Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) in All Participants — 28.9 Percentage of participants
Phase 2 N=37 Nab-Paclitaxel, Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer
Head and Neck Cancer
Primary: Progression Free Survival (PFS) — 60 percentage of participants
Phase 2 N=72 Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer
Castration-resistant Prostate Cancer · Stage IV Prostate Cancer
Primary: Change in PSA Level — -1.19; -1.59 log ratio — p=<0.10
Phase 2 N=77 Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
Multiple Myeloma and Plasma Cell Neoplasm
Primary: Best Response Prior to Tandem Autologous Stem Cell Transplant — 1; 4; 62; 1 Participants
Phase 2 N=40 Experimental Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray in Normal Volunteers
Anesthesia
Primary: Duration of Anesthesia as Measured by Pin Prick Test (PPT) for One Spray CTY-5339-A Compared to One Spray CTY-5339-CB — 17.9; 16.4 minutes — p=0.322
Phase 2 N=134 Efficacy and Safety Study of F373280
Atrial Fibrillation
Primary: Time to First Atrial Fibrillation (AF) Recurrence or Atrial Flutter Emergence Defined by the Time to First Episode of AF or Atrial Flutter Lasting for at Least 10…
Phase 2 N=148 Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma
Carcinoma of Urinary Tract · Urethral Carcinoma · Carcinoma of Ureter
Primary: Progression-Free Survival (PFS) — 2.8; 5.4; 1.6 months
Phase 2 N=365 A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
Group B Streptococcal Infections
Primary: Percentage of Participants With Clinical Laboratory Abnormalities at 1-Week After Vaccination as Measured by Food and Drug Administration (FDA) Grade — 0; 6.3; 12.5; 0…
Phase 2 N=95 Gabapentin as an Adjunct to Perioperative Pain Management Regimens for Uterine Aspiration
Other Abortion · Spontaneous Abortion
Primary: Pain Score on 100-mm VAS (Visual Analog Scale) at 5 Minutes Post-procedure — 35.7; 37.1 score on a scale — p=0.56